Search Result

Results for "

Zonisamide

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Calcium Channel (1) Carbonic Anhydrase (5) CXCR (2) Drug Intermediate (1) Fluorescent Dye (1) Isotope-Labeled Compounds (3) Melanocortin Receptor (1) Neuropeptide Y Receptor (3) Parasite (1) Reference Standards (1) Sodium Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Metabolic Disease (2) Neurological Disease (9)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0124

*Zonisamide* 3 Publications Verification AD 810; CI 912	Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124S

Zonisamide-d4	Isotope-Labeled Compounds Carbonic Anhydrase Calcium Channel Sodium Channel	Neurological Disease
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-B0124S1

Zonisamide-13C2,15N	Isotope-Labeled Compounds	Others
Zonisamide- ¹³C2, ¹⁵N is deuterated labeled Zonisamide.

HY-W103317

1,2-Benzisoxazole Indoxazene	Drug Intermediate	Neurological Disease
1,2-Benzisoxazole (Indoxazene) is a potential substrate of rabbit liver aldehyde oxidase. 1,2-Benzisoxazole was used in the discovery and development of zonisamide (HY-B0124) for the study of epilepsy and Parkinson's disease .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-B0124A

Zonisamide sodium AD 810 sodium; CI 912 sodium	Carbonic Anhydrase Apoptosis	Cardiovascular Disease Neurological Disease
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124R

Zonisamide (Standard) AD 810 (Standard); CI 912 (Standard)	Reference Standards Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-B0124S2

Zonisamide-13C6 AD 810-¹³C₆; CI 912-¹³C₆	Isotope-Labeled Compounds Carbonic Anhydrase Apoptosis	Neurological Disease
Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

Cat. No.	Product Name	Target	Research Area

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .

HY-P4070

Insulin icodec	Peptides	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec can be used for the research of type 2 diabetes .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P11293

DOTA-GGNle-CycMSHhex	Melanocortin Receptor	Cancer
DOTA-GGNle-CycMSHhex is a melanocortin-1 receptor (MC1R)-targeting peptide that can be radionuclide-labeled for melanoma imaging .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

Cat. No.	Product Name	Chemical Structure

HY-B0124S

Zonisamide-d4
Zonisamide-d₄ is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonic anhydrase (CA), with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .

HY-B0124S1

Zonisamide-13C2,15N
Zonisamide- ¹³C2, ¹⁵N is deuterated labeled Zonisamide.

HY-B0124S2

Zonisamide-13C6
Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

Zonisamide-13C6

Zonisamide- ¹³C₆ (AD 810- ¹³C₆) is ¹³C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with K_is of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.